Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer
/PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...
Source: prnewswire.com
Page 2 - Adcendo News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Adcendo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Adcendo Today - Breaking & Trending Today
Adcendo presents Data on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting
/PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...
Source: prnewswire.com
Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders
/PRNewswire/ -- Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers,...
Source: prnewswire.com
Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders
- Building the team with experienced biotech experts and renowned leaders in the ADC field - Underscores company's commitment to progressing lead program on novel ADC target uPARAP COPENHAGEN
Source: finanznachrichten.de
Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers
Share this article Share this article COPENHAGEN, Denmark, April 29, 2021 /PRNewswire/ -- Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The investment was led by Novo Seeds, the early-stage investment and company creation team of Novo Holdings, and Ysios Capital, along with RA Capital Management, HealthCap and Gilde Healthcare. The company was initially incubated and funded at the BioInnovation Institute (BII). The new financing, which is th...
Source: prnewswire.com